| Apr. 1988 |
LTT Research Institute was established for the purpose of support of research and development of DDS-related technologies. |
| Jun. 1988 |
Limethason®, a DDS product developed by LTT, was marketed by Mitsubishi Tanabe Pharma Corp. (former Green Cross Corp.). |
| July. 1988 |
Haloart®, a DDS product developed by LTT, was marketed by Taiho Pharmaceutical Co., Ltd. |
| Oct. 1988 |
Palux Injection®, a DDS product developed by LTT, was marketed by Taisho Pharmaceutical Co., Ltd. |
| Nov. 1988 |
Liple Injection®, a DDS product developed by LTT, was marketed by Mitsubishi Tanalo Pharma Corp. A contract research agreement was concluded with St. Marianna University. |
| Oct. 1990 |
Institute of Medical Science St. Marianna Univ. School of Medicine was established. |
| Jun. 1992 |
Ropion Injection®, a DDS product developed by LTT, was marketed by Kaken Pharmaceutical Co., Ltd. |
| Mar. 1995 |
Beijing Tide Pharmaceutical Co., Ltd. was established jointly with China-Japan Friendship Hospital, Beijing, China. Manufacturing of Lipo-PGE1 product was started in China with the
technical support from Taisho Pharmaceutical Co., Ltd. |
| Apr. 1997 |
The head office was moved to Nagata-cho, Chiyoda-ku, Tokyo. |
| Sep. 1998 |
Farnezone and Farnerate were marketed by Taiho Pharmaceutical Co., Ltd. and Dainippon Sumitomo Pharmaceutical Co., Ltd., respectively. |
| Oct. 2001 |
A contract research agreement was concluded with DDS Institute, Jikei University. |
| Nov. 2001 |
The head office was moved to Atago, Minato-ku, Tokyo. |
| Jan. 2003 |
LTT Bio-Pharma was founded by corporate separation from LTT Research Institute to transfer the pharmaceutical business. |
| Nov. 2004 |
LTT Bio-Pharma was listed on TSE Mothers. |
| Jun. 2005 |
Perfect Lift AA, a DDS product developed by LTT, was marketed by Rohto Pharmaceutical Co., Ltd. |
| Oct. 2005 |
Sole Co., Ltd. (consolidated subsidiary) was established for the purpose of management of pharmacies. |
| Mar. 2006 |
I&L Anti-Aging Management Co., Ltd. was established jointly for the purpose of support of anti-aging clinics. |
| Jun. 2006 |
A joint enterprise agreement was concluded with Machine Parts Co., Ltd. for manufacturing and sales of MH punch. |
| Aug. 2006 |
MH punch was marketed. |
| Nov. 2006 |
An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan. This study showed that PC-SOD was effective for ulcerative colitis. |
| Dec. 2006 |
LTT Bio-Pharma ties up with Cipla Ltd., India on Nanosteroids. |
| May. 2007 |
A share exchange agreement was concluded to take over Asclepius Ltd. as a wholly-owned subsidiary of LTT Bio-Pharma. |
| Mar. 2008 |
EIP punch which allows tableting without St-Mg was marketed. |
| Mar. 2008 |
Asclepius Ltd. files for bankruptcy. |
| May. 2008 |
Dr. Yutaka Mizushima passed away for heart failure. |
| Jun. 2008 |
An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan.
This study showed that PC-SOD was effective for idiopathic intersttial pheumonia. |
| Oct. 2008 |
Machine Parts Marketing Co.,Ltd was established for the purpose of sales of EIP punch etc.
|
| Feb. 2009 |
The head office was moved to Kaigan,Minato-ku,Tokyo.
|
